We are live on ! Find out more
SBBP

Strongbridge Biopharma plc.
SBBP

Delisted

SBBP was delisted on the 5th of October, 2021.

65 hedge funds and large institutions have $273M invested in Strongbridge Biopharma plc. in 2018 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 25 increasing their positions, 11 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

127% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 11

122% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 9

67% more funds holding in top 10

Funds holding in top 10: 35 (+2)

44% more capital invested

Capital invested by funds: $190M → $273M (+$82.9M)

20% more funds holding

Funds holding: 5465 (+11)

Holders
65
Holders Change
+11
Holders Change %
+20.37%
% of All Funds
1.49%
Holding in Top 10
5
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+66.67%
% of All Funds
0.11%
New
20
Increased
25
Reduced
11
Closed
9
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Morgan Stanley
26
Morgan Stanley
New York
$973K +$291K +38,836 +54%
Geode Capital Management
27
Geode Capital Management
Massachusetts
$889K +$160K +21,432 +27%
Vanguard Group
28
Vanguard Group
Pennsylvania
$796K +$100K +13,394 +17%
EI
29
EAM Investors
California
$678K +$573K +76,595 New
Bank of New York Mellon
30
Bank of New York Mellon
New York
$599K +$144K +19,240 +40%
Deutsche Bank
31
Deutsche Bank
Germany
$568K +$65.1K +8,698 +16%
Charles Schwab
32
Charles Schwab
California
$514K +$86.8K +11,600 +25%
California State Teachers Retirement System (CalSTRS)
33
California State Teachers Retirement System (CalSTRS)
California
$378K +$27.9K +3,733 +10%
PCM
34
Prelude Capital Management
New York
$372K +$315K +42,079 New
Invesco
35
Invesco
Georgia
$356K +$301K +40,181 New
TA
36
Teachers Advisors
New York
$334K
Marshall Wace
37
Marshall Wace
United Kingdom
$332K +$281K +37,500 New
Goldman Sachs
38
Goldman Sachs
New York
$272K -$50.9K -6,793 -18%
SIM
39
Spark Investment Management
New York
$240K +$204K +27,200 New
New York State Common Retirement Fund
40
New York State Common Retirement Fund
New York
$229K +$108K +14,400 +125%
ProShare Advisors
41
ProShare Advisors
Maryland
$216K +$13.2K +1,757 +8%
GIP
42
Granite Investment Partners
California
$215K +$182K +24,355 New
Manulife (Manufacturers Life Insurance)
43
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$206K +$13K +1,742 +8%
RhumbLine Advisers
44
RhumbLine Advisers
Massachusetts
$192K +$34.3K +4,576 +27%
Barclays
45
Barclays
United Kingdom
$188K +$128K +17,125 +430%
Citadel Advisors
46
Citadel Advisors
Florida
$166K +$141K +18,813 New
AIG
47
American International Group
New York
$159K +$9.52K +1,271 +8%
State of Wisconsin Investment Board
48
State of Wisconsin Investment Board
Wisconsin
$142K
Two Sigma Investments
49
Two Sigma Investments
New York
$130K +$110K +14,700 New
OC
50
Oppenheimer & Co
New York
$119K +$101K +13,436 New

SBBP Hedge Fund Activity: Q1 2018 in Review

65 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Strongbridge Biopharma plc. (SBBP) for Q1 2018, worth a combined $273M — up 44% from $190M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new SBBP positions and 9 closed out — a net gain of 11 holders — while 25 added to existing stakes and 11 trimmed.

The largest buyer was Lyon Street Capital, adding an estimated $13.3M. The largest seller was Vivo Capital, cutting an estimated $4M.

  • 65 institutional investors held Strongbridge Biopharma plc. (SBBP) as of Q1 2018, up from 54 in Q4 2017.
  • Funds reported $273M of Strongbridge Biopharma plc. stock for Q1 2018, up 44% quarter-over-quarter.
  • 20 funds opened new Strongbridge Biopharma plc. positions in Q1 2018 and 9 closed out, a net change of +11 holders.
  • The largest Strongbridge Biopharma plc. buyer in Q1 2018 was Lyon Street Capital, an estimated $13.3M added.
  • The largest Strongbridge Biopharma plc. seller in Q1 2018 was Vivo Capital, an estimated $4M sold.

Based on aggregated 13F filings for Q1 2018.